| Y/e 31 Mar( In .Cr) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|---|
Equity Capital | 16.48 | 16.48 | 16.47 | 16.47 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 10,793.56 | 9,738.63 | 8,978.82 | 7,936.83 |
Net Worth | 10,810.04 | 9,755.11 | 8,995.29 | 7,953.3 |
Minority Interest | ||||
Debt | 2.75 | 5.23 | 3.66 | 4.45 |
Deferred Tax Liability Net | 130.48 | 125.38 | 116.54 | 106.92 |
Total Liabilities | 10,943.27 | 9,885.72 | 9,115.49 | 8,064.67 |
Fixed Assets | 1,826.06 | 1,787.19 | 1,813.73 | 1,747.76 |
Intangible Assets | ||||
Investments | 3,292.55 | 2,789.57 | 2,385.74 | 8.16 |
Deferred Tax Asset Net | 15.73 | 8.98 | 8.28 | 22.71 |
Networking Capital | 2,631.28 | 2,867.34 | 3,309.2 | 2,519.04 |
Inventories | 1,265.2 | 1,254.23 | 1,260.21 | 1,945.3 |
Inventory Days | ||||
Sundry Debtors | 1,520.69 | 1,142.9 | 1,171.4 | 862.84 |
Debtor Days | ||||
Other Current Assets | 525.08 | 1,015.1 | 1,311.47 | 442.12 |
Sundry Creditors | -497.37 | -389.82 | -289.7 | -604.91 |
Creditor Days | ||||
Other Current Liabilities | -182.32 | -155.07 | -144.18 | -126.31 |
Cash | 3,177.64 | 2,432.62 | 1,598.55 | 3,767 |
Total Assets | 10,943.26 | 9,885.7 | 9,115.5 | 8,064.67 |
The European business reported a 54 percent year on year surge in topline during the quarter.
Here are some of the stocks that may see significant price movement today: Infosys, Tata Steel, Cipla Limited, etc.
Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.
Here are some of the stocks that may see significant price movement today: Avenue Supermarts, BEML, Gland Pharma, etc.
The receipt of the EIR marks the formal closure of the US health regulator’s pre-approval inspection, which was conducted between February 19 and February 25, 2025.
Here are some of the stocks that may see significant price movement today: Hindustan Aeronautics, Gland Pharma, REC, etc.
Gland Pharma also established that its version is bioequivalent and therapeutically equivalent to the reference listed drug.
Gland Pharma net profit was at ₹186.5 crore as against ₹192.4 crore in the year-ago quarter of FY24.
Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US
The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
